Back to Feed
总结
多家媒体聚焦在美国旧金山举行的摩根大通医疗健康大会（JPM），称其是生物医药与医疗健康投融资的关键“开年场”：药企、创新药与生物科技公司将集中与投资人会面，发布战略与管线进展，寻求融资、合作授权与并购机会。报道同时指出，大会能影响市场情绪与交易节奏，但并非决定企业成败的唯一节点；2026年业内期待更大规模并购回归，仍将受政策与监管、利率环境及审批不确定性左右。
正文
Why the JP Morgan conference is important - but not make-or-break statnews.com Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 Yahoo Finance Healthy Returns: What to expect from pharma at the JPM conference CNBC At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun BioSpace JPM 2026: What to know about the San Francisco conference Modern Healthcare
发布时间：